Agilent receives approval for genetisure dx postnatal assay in japan

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) announced it has obtained clearance from the ministry of health, labour and welfare (mhlw) in japan for the genetisure dx postnatal assay – a microarray-based assay for diagnostic use. this assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. the company also announced that it has register
A Ratings Summary
A Quant Ranking